Cencora stock
CORNYSECencora, Inc., HealthcareISIN US03073E1055
74Score 74 out of 100, Strong
Price and trend
84 / 100
Price history
−4.2% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 10% above it.
Since October 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 57).
The price is 6.6% below its 52-week high. Largest decline in 20 years: 51% (April 2007 to November 2008).
Chart figures for advanced users
- SMA 50$326.47
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$316.69
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)57
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$252.74
- The lowest closing price of the last twelve months.
- Resistance$374.75
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Cencora, Inc. belongs to the Medical (Distribution) industry (United States) and, with a market value of $66.77B, is number 2 of 17 companies in its industry on MEQIRI.
- In fiscal 2026 it reported revenue of $337.4B (up 5% year on year) and earnings of $3.48B (up 124.2%).
- For fiscal 2027, analysts expect on average revenue of $352.05B (up 4.3%) and adjusted earnings per share of $19.73 (up 9.8%).
Show more
- MEQIRI Score 74 out of 100 (Strong): rank 82 of 714 in Healthcare, median 53.
- The P/E is 19.3 (Medical (Distribution) median 26.9, own median of recent years 20.2).
- Our model puts fair value at $467.63, with the price 25% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- High return on capitalReturn on invested capital 33.1% in fiscal 2026, Medical (Distribution) median 7.3%.Profitability 58
- Reliable dividendNo dividend cut for 24 years.Capital allocation 90
- Earnings per share growingUp 19.2% a year since 2021.Growth 73
Weaknesses
- High debtDebt 3.06 times equity (latest quarter), Medical (Distribution) median 0.74.Stability 49
Its standout strengths are fundamentals and capital allocation, while stability holds the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among stocks ranked 101 to 1,000.
From 2016 to 2025, 9 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
What lowers it
- solid fundamentals
Valuation
Valuation signal
Significantly undervaluedIn our model the price counts as cheap below $359.72 and expensive above $668.04 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $446.86 (cash-flow model) and $488.40 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 9%. At 10% the fair value would be $430.83, at 8% it would be $522.16.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (26.9).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In fiscal 2026, revenue rose 5% on the prior year. Revenue has grown solidly since 2007, at about 9% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2026: gross 4%, operating 1%, net 1%.
Debt & balance sheet
latest quarterMeaningfully leveraged, but the interest bill is comfortably covered.
Earnings
- Next earnings
- 3 Feb 2027in 83 days
- Last reported
- 4 Nov 2026EPS reported $4.66 (expected $4.58)in line with expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $19.73−0.1%
- Revenue
- $352.05B0.0%
- Earnings per share
- $21.76−0.2%
- Revenue
- $367.1B−0.4%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +6.1%Fiscal 2026 adjusted EPS raised to $17.75 to $17.95 from $17.70 to $17.90; operating income growth now 13% to 14%, with the bottom end raised.
“Driven by our strong performance and opportunistic share repurchases, we are pleased to raise our full year adjusted EPS guidance range to $17.75 to $17.95, up from $17.70 to $17.90.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 5 Aug 2026 (fiscal Q3 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
2 insiders bought on the open market in the last 6 months, $2.31M in total. 3 insiders sold, $5.02M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Krikorian LazarusSale
2 Nov 2026, SVP & Chief Accounting Officer
- Shares
- 986
- Price
- $330.96
- Value
- $326,327
- Krikorian LazarusSale
1 Oct 2026, SVP & Chief Accounting Officer
- Shares
- 986
- Price
- $303.18
- Value
- $298,935
- Greenberg Lon RSale
16 Sept 2026, Board
- Shares
- 1,280
- Price
- $321.30
- Value
- $411,264
Show 5 more
- Krikorian LazarusSale
1 Sept 2026, SVP & Chief Accounting Officer
- Shares
- 985
- Price
- $325.97
- Value
- $321,080
- Campbell Elizabeth SSale
24 Aug 2026, Executive Vice President
- Shares
- 11,300.47
- Price
- $324.12
- Value
- $3.66M
- Tyler Lauren MPurchase
22 Jun 2026, Board
- Shares
- 550
- Price
- $270.23
- Value
- $148,627
- Durcan Dermot MarkPurchase
18 Jun 2026, Board
- Shares
- 4,000
- Price
- $274.19
- Value
- $1.1M
- Durcan Dermot MarkPurchase
28 May 2026, Board
- Shares
- 4,000
- Price
- $266.26
- Value
- $1.07M
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Cencora
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 74
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Distribution)
The next larger and next smaller companies by market value
- McKessonMCK $124.67B76
- Cardinal HealthCAH $64.13B69
- Henry ScheinHSIC $9.77B66
- Shanghai Pharmaceuticals Holding601607.SS $9.01B53
- Sinopharm Group1099.HK $6.67B58
- GalenicaGALE.SW $5.42B60
- AmplifonAMP.MI $3.68B49
- Asker Healthcare GroupASKER.ST $2.87B61
ETFs that hold Cencora
Held by 128 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Harbor Health Care UCITS ETF AccW311 | 2.35% | 0.89% | €11.61M |
| iShares MSCI World Health Care Sector Advanced UCITS ETFCBUF | 1.68% | 0.18% | €837.43M |
| iShares Edge MSCI USA Minimum Volatility Advanced UCITS ETFMVEA | 1.33% | 0.20% | €117.82M |
Show 5 more
| iShares Edge MSCI World Minimum Volatility Advanced UCITS ETF USD (Acc)MVEW | 1.26% | 0.30% | €306.37M |
| JPM Global Equity Premium Income Active UCITS ETF USD (dist)JGPI | 1.21% | 0.35% | €1.55B |
| iShares Edge MSCI World Minimum Volatility UCITS ETF USD (Dist)UEEH | 1.14% | 0.30% | €12.76M |
| Xtrackers MSCI World Minimum Volatility UCITS ETF 1CXDEB | 1.10% | 0.25% | €1.38B |
| iShares S&P 500 Health Care Sector UCITS ETFQDVG | 0.98% | 0.15% | €3.27B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 30 Sep 2026
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 18 Oct 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.